company background image
KZA

Kazia Therapeutics ASX:KZA Stock Report

Last Price

AU$0.15

Market Cap

AU$39.0m

7D

10.7%

1Y

-13.9%

Updated

03 Oct, 2023

Data

Company Financials +

KZA Stock Overview

Kazia Therapeutics Limited operates as a biotechnology company, develops anti-cancer drugs.

KZA fundamental analysis
Snowflake Score
Valuation3/6
Future Growth3/6
Past Performance0/6
Financial Health3/6
Dividends0/6

Kazia Therapeutics Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Kazia Therapeutics
Historical stock prices
Current Share PriceAU$0.15
52 Week HighAU$0.24
52 Week LowAU$0.07
Beta2
1 Month Change-3.13%
3 Month Change-8.82%
1 Year Change-13.89%
3 Year Change-80.86%
5 Year Change-65.56%
Change since IPO-95.44%

Recent News & Updates

Recent updates

We're Not Worried About Kazia Therapeutics' (ASX:KZA) Cash Burn

Jun 24
We're Not Worried About Kazia Therapeutics' (ASX:KZA) Cash Burn

We're Not Worried About Kazia Therapeutics' (ASX:KZA) Cash Burn

Feb 24
We're Not Worried About Kazia Therapeutics' (ASX:KZA) Cash Burn

We Take A Look At Why Kazia Therapeutics Limited's (ASX:KZA) CEO Compensation Is Well Earned

Nov 03
We Take A Look At Why Kazia Therapeutics Limited's (ASX:KZA) CEO Compensation Is Well Earned

We Think Kazia Therapeutics (ASX:KZA) Can Easily Afford To Drive Business Growth

Sep 23
We Think Kazia Therapeutics (ASX:KZA) Can Easily Afford To Drive Business Growth

We Think Kazia Therapeutics (ASX:KZA) Can Afford To Drive Business Growth

May 04
We Think Kazia Therapeutics (ASX:KZA) Can Afford To Drive Business Growth

When Will Kazia Therapeutics Limited (ASX:KZA) Turn A Profit?

Mar 27
When Will Kazia Therapeutics Limited (ASX:KZA) Turn A Profit?

Could The Kazia Therapeutics Limited (ASX:KZA) Ownership Structure Tell Us Something Useful?

Feb 28
Could The Kazia Therapeutics Limited (ASX:KZA) Ownership Structure Tell Us Something Useful?

What Can We Learn About Kazia Therapeutics' (ASX:KZA) CEO Compensation?

Feb 01
What Can We Learn About Kazia Therapeutics' (ASX:KZA) CEO Compensation?

We Think Kazia Therapeutics (ASX:KZA) Can Afford To Drive Business Growth

Jan 06
We Think Kazia Therapeutics (ASX:KZA) Can Afford To Drive Business Growth

Bullish: Analysts Just Made An Incredible Upgrade To Their Kazia Therapeutics Limited (ASX:KZA) Forecasts

Dec 11
Bullish: Analysts Just Made An Incredible Upgrade To Their Kazia Therapeutics Limited (ASX:KZA) Forecasts

Kazia Therapeutics Limited (ASX:KZA): When Will It Breakeven?

Nov 26
Kazia Therapeutics Limited (ASX:KZA): When Will It Breakeven?

Shareholder Returns

KZAAU BiotechsAU Market
7D10.7%-2.4%-0.6%
1Y-13.9%-12.3%7.7%

Return vs Industry: KZA underperformed the Australian Biotechs industry which returned -12.3% over the past year.

Return vs Market: KZA underperformed the Australian Market which returned 7.7% over the past year.

Price Volatility

Is KZA's price volatile compared to industry and market?
KZA volatility
KZA Average Weekly Movement13.3%
Biotechs Industry Average Movement10.9%
Market Average Movement8.4%
10% most volatile stocks in AU Market15.8%
10% least volatile stocks in AU Market3.1%

Stable Share Price: KZA is more volatile than 75% of Australian stocks over the past 3 months, typically moving +/- 13% a week.

Volatility Over Time: KZA's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of Australian stocks.

About the Company

FoundedEmployeesCEOWebsite
1994n/aJohn Friendhttps://www.kaziatherapeutics.com

Kazia Therapeutics Limited operates as a biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma, diffuse intrinsic pontine glioma/advanced solid tumors, atypical teratoid rhabdoid tumor, brain metastases, triple negative breast cancer, and primary central nervous system lymphoma. It is also developing EVT801, a small molecule targeted therapeutic vascular endothelial growth factor receptor 3 inhibitor.

Kazia Therapeutics Limited Fundamentals Summary

How do Kazia Therapeutics's earnings and revenue compare to its market cap?
KZA fundamental statistics
Market CapAU$39.00m
Earnings (TTM)-AU$20.47m
Revenue (TTM)AU$555.00

Over9,999x

P/S Ratio

-1.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
KZA income statement (TTM)
RevenueAU$555.00
Cost of RevenueAU$0
Gross ProfitAU$555.00
Other ExpensesAU$20.47m
Earnings-AU$20.47m

Last Reported Earnings

Jun 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.087
Gross Margin100.00%
Net Profit Margin-3,687,419.82%
Debt/Equity Ratio14.9%

How did KZA perform over the long term?

See historical performance and comparison